Cg Oncology, Inc.

This phase 3 trial is testing a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not improve after standard BCG therapy. The treatment uses a modified virus to target and destroy cancer cells. About 190 pa…

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…